1. The prospect of a US-Iran framework agreement remains under review and intensive negotiations, involving representatives from Qatar, Iran, and the US.
2. Eli Lilly announced that its Jaypirca (pirtobrutinib) study met its primary endpoint, significantly reducing the risk of CLL/SLL disease progression by 45%.
3. RIF's price has surged over 45% in the past 24 hours, now trading at $0.1137 with a market capitalization of $111 million.
US-Iran Deal Progresses, Eli Lilly's Drug Shows Strong Efficacy, RIF Crypto Surges 45%
